Here is a selection of recent executive hires, promotions and layoffs occurring across the healthcare industry.

For the August episode, we discuss some recent executive appointments occurring in the healthcare sector, as well as layoffs affecting the industry. We also hear from Andrew Trister, who just became Verily’s chief scientific officer.

OneOncology recently announced that it is deploying Verily’s clinical trial management platform across 11 of its community oncology clinics. Adopting Verily’s software will hopefully make clinical trial management much easier for OneOncology, which would allow the company to further democratize trials to improve health equity, the company’s chief medical officer said.

Th FDA granted another 510(k) clearance to iRhythm Technologies for its AI-powered software system designed for use with Verily’s irregular pulse tracking watch. The clearance is for an algorithm that categorizes patients’ AFib by analyzing how much of it they experience over time.

A study published by Verily researchers showed that some smartphone metrics, such as sentiment in weekly voice diaries, matched up with the severity of users’ depression as determined by PHQ-9 scores. Even if these technologies could be used to track mental health, it’s not clear how they will fit into physician workflows or how comfortable people will be using their smartphones in this way. 

People who access Onduo through their employer will have access to the wearables and Fitbit’s subscription program. Google closed its acquisition of Fitbit earlier this year, and Onduo is a subsidiary of Google’s sister company, Verily.

They plan to commercialize the decision support software, which would surface relevant patient records and recommendations from Mayo Clinic specialists. To start, they will focus on cardiometabolic conditions.

Verily’s recent moves have signaled the company’s interest in supporting decentralized clinical trials and real-world studies. Now the life sciences subsidiary of Alphabet is bolstering its capabilities in these areas with the acquisition of startup SignalPath.

The companies will launch a randomized, controlled trial to see how access to gum irrigation and a smart toothbrush changes their oral health, blood sugar and artery health. 

Verily become part of a six-year collaboration between Google Cloud and Highmark Health. A big part of the partnership will be Verily’s platform for managing chronic conditions, Onduo.

Verily’s virtual diabetes platform, Onduo, is expanding to support additional conditions and languages, Onduo’s CEO Vindell Washington shared. How will the company differentiate itself among a growing number of multi-condition platforms, such as Livongo and Omada?

Alphabet and other investors poured $700 million in funding into Verily last week. The company, which is Alphabet’s life sciences subsidiary, plans to pour some of the funds into supporting Covid-19 vaccine studies and programs for businesses.

Tom Stanis, Verily’s co-founder and former head of software, left the Alphabet subsidiary in February to found a new healthcare startup. Called Story Health, his new startup is focused on providing care in the gaps between specialty visits.

Google’s sister company launched a program in California and other states to help route patients to nearby coronavirus testing. Dr. Vivian Lee, president of health platforms for Verily, shared lessons learned from that effort and Verily’s work with schools and businesses.

Alphabet’s healthcare subsidiary, Verily, will partner with Swiss Re Corporate Solutions to create a new stop-loss insurance company. The new entity, called Coefficient, will use data analytics to help self-funded companies manage unexpected areas of cost.

Verily, Alphabet’s life sciences arm, is launching a new study to better understand the immune response to Covid-19 and gain more information on the accuracy of tests.

After declaring a state of emergency on Friday, Trump announced that Google would be building a website that could route users to drive-thru testing sites for COVID-19. Alphabet’s subsidiary, Verily, said the tool was in the early stages of development, and that it planned to roll out testing in the Bay Area.

The latest round of funding, led by Chinese investors, brings the total amount of money raised by the company, co-founded by CRISPR pioneer Jennifer Doudna, to more than $70 million.

The partnership adds to Verily’s growing work in value-based reimbursement.

Color vice president for research and scientific affairs Alicia Zhou explained that there is an ethical obligation to provide information on actionable genes, but costs and logistics have previously made doing so prohibitive.

Verily is being paid by iRhythm Technologies to develop a tool by improving existing hardware and software to effectively diagnose patients with asymptomatic atrial fibrillation.

The regulator is opening up the program to 510(k) submissions, instead of its initial focus on companies moving through the De Novo regulatory pathway.

The company just announced strategic alliances with Novartis, Otsuka, Pfizer and Sanofi to develop new clinical research programs utilizing the Project Baseline platform across therapeutic areas ranging from cardiovascular disease to oncology to mental health.

The organizations have announced that the first real-world clinical use of the algorithm is happening at the Aravind Eye Hospital in Madurai, India.

Redwood City, California-based Auris Health may also receive up to $2.35 billion in additional payments dependent on hitting certain predetermined milestones.

While the Study Watch was designed as investigational tool, it’s likely the company will integrate features developed on the device onto its more consumer-oriented offerings.

At the CES Digital Health Summit, Daniel Kraft and leaders from Fitbit Health Solutions, Verily and Akili Interactive explored how far we’ve come and where we’re going when it comes to digital health.

San Diego-based Dexcom said at the annual J.P. Morgan Healthcare Conference in San Francisco that it’s first-gen product co-developed by Alphabet’s Verily may never get launched in the U.S.

Alphabet CFO Ruth Porat and Silver Lake Managing Director Egon Durban will be nominated to join Verily’s operating board.

The initial major focus of the partnership will be medication adherence, which costs the U.S. healthcare system nearly $300 billion annually